PX1 Research provides high-purity, research-grade Bronchogen for qualified laboratory institutions evaluating bronchial cell dynamics, mucociliary clearance, and airway epithelial remodeling. Manufactured in compliant USA facilities, our Bronchogen undergoes rigorous analytical testing to ensure lot-to-lot consistency in preclinical experimental models.
PX1 Research provides high-purity, research-grade Bronchogen for qualified laboratory institutions evaluating bronchial cell dynamics, mucociliary clearance, and airway epithelial remodeling. Manufactured in compliant USA facilities, our Bronchogen undergoes rigorous analytical testing to ensure lot-to-lot consistency in preclinical experimental models.
PX1 Research is a professional manufacturer supplying research-grade Bronchogen to academic, pharmaceutical, and institutional laboratories. In preclinical respiratory literature, Bronchogen is investigated for its capacity to modulate bronchial mucosal gene expression, goblet cell hypersecretion, and mucus visco-elasticity in models evaluating expectoration dynamics and epithelial barrier integrity.
As a synthetic short peptide belonging to the bioregulator class, Bronchogen serves as a precise biochemical tool in controlled laboratory setups. Preclinical studies suggest that short peptide bioregulators interact directly with genomic DNA histones and promoter regions within respiratory tissue cultures, rendering them key candidates for investigating cellular repair, inflammatory biomarker suppression, and mucociliary clearance mechanisms in vitro.
Bronchogen is a short peptide sequence (Ala-Glu-Asp-Leu) structurally engineered to match targeted bioregulatory sequences originally isolated from bronchial mucosal tissues. In vitro assays demonstrate that short peptide chains like Bronchogen penetrate nuclear membranes within pulmonary epithelial cells without requiring complex transport vehicles.
Upon entering the cell nucleus, the peptide sequence selectively binds to specific DNA promoter regions, influencing chromatin condensation and RNA polymerase activity. In vitro data indicate that this interaction regulates the transcriptomic output of genes responsible for mucin protein synthesis (such as MUC5AC and MUC5B), surfactant protein expression, and pro-inflammatory cytokine secretion (including IL-8 and TNF-alpha).
By modulating the transcriptional rate of mucin-encoding genes, researchers utilize Bronchogen to examine pathways controlling excessive mucus production and cellular hyper-reactivity in primary lung cell cultures and animal models of airway inflammation.
In preclinical studies using rodent models of chronic pulmonary inflammation, administration of research-grade Bronchogen was observed to decrease goblet cell hyperplasia within the tracheal and bronchial epithelium. Goblet cell proliferation directly correlates with excess mucus accumulation; thus, regulating this population provides a mechanistic explanation for reduced expectoration volumes observed in animal models.
Furthermore, experimental models analyzing ciliary beat frequency (CBF) in air-liquid interface (ALI) bronchial cultures indicate that Bronchogen exposure preserves structural integrity in ciliated epithelial cells. Enhanced ciliary dynamics combined with optimized mucus viscosity allow for improved clearance of cellular debris and exudate across the respiratory tract.
Researchers analyzing respiratory mechanics also report that Bronchogen treatment in animal models of induced bronchospasm attenuates local oxidative stress markers, such as malondialdehyde (MDA), while augmenting endogenous antioxidant activity via superoxide dismutase (SOD) pathways. These biochemical shifts help stabilize the epithelial barrier during oxidative challenge assays.
Selecting a professional manufacturer for specialized compounds like Bronchogen requires rigorous evaluation of synthesis methodology, analytical verification, and contamination control. Respiratory tissue cultures and primary cell lines are exceptionally sensitive to minute chemical impurities, residual trifluoroacetic acid (TFA), and bacterial endotoxins.
A reliable peptide manufacturer must maintain total supply chain transparency, utilizing solid-phase peptide synthesis (SPPS) protocols optimized to yield exact amino acid sequence fidelity. Inferior manufacturing processes often yield deletion sequences or truncated peptides that compete for receptor or DNA-binding sites, confounding experimental outcomes.
PX1 Research enforces strict manufacturing standards across all production runs, ensuring that investigators receive compounds with verified sequence identity, optimal solubility characteristics, and predictable bioactivity for repeatable scientific trial runs.
At PX1 Research, every batch of Bronchogen is synthesized in USA-based GMP-compliant facilities and thoroughly tested by independent ISO 17025 accredited laboratories. We provide comprehensive, lot-specific Certificates of Analysis (COAs) to validate the chemical integrity of our inventory.
Our analytical verification workflow includes:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity exceeding 98%. 2. Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight and structural identity. 3. Chromogenic Limulus Amebocyte Lysate (LAL) testing to guarantee endotoxin levels remain below 0.01 EU/mg. 4. Residual solvent and TFA counter-ion quantification to protect delicate cell culture models from vehicle-induced toxicity.
To review detailed specifications or purchase validated lots for ongoing laboratory projects, visit our complete catalog of research peptides or consult our dedicated research library for technical background data.
Within bioregulatory peptide research, Bronchogen belongs to a distinct category of organ-specific peptide sequences designed to target localized tissue dynamics. To establish proper experimental controls, researchers frequently evaluate Bronchogen alongside comparable peptide bioregulators across various organ systems.
For example, while Bronchogen specifically modulates pulmonary epithelial gene expression and expectoration parameters, Chonluten is another short peptide frequently evaluated in bronchial tissue models for its structural repair mechanisms. Similarly, compounds such as Cartalax are deployed in connective tissue assays to target chondrocyte extracellular matrix synthesis, whereas Thymogen is utilized in immunological models to evaluate T-cell differentiation and cytokine balancing.
Evaluating these parallel compounds allows laboratories to establish tissue selectivity controls, verifying whether observed transcriptional changes are specific to bronchial targets or represent generalized bioregulatory cellular signals.
Bronchogen is supplied as a lyophilized, sterile powder designed for high stability during transport and storage. Proper laboratory preparation is essential to prevent peptide degradation, aggregation, or bacterial contamination during reconstitutions.
Laboratory Best Practices for Reconstitution:
• Solvent Selection: Reconstitute lyophilized Bronchogen using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory applications or sterile Phosphate-Buffered Saline (PBS, pH 7.4) for immediate cell culture assays. • Reconstitution Method: Allow the vial and solvent to reach room temperature prior to fluid addition. Direct the diluent stream slowly down the inner glass wall of the vial rather than directly onto the lyophilized cake. • Dissolution: Gently swirl or roll the vial between palms until dissolved. Avoid vigorous vortexing or shaking, which can induce physical shear stress and peptide denaturation. • Aliquoting & Storage: Stock solutions should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles. Store reconstituted aliquots at -20°C or -80°C for long-term storage stability.
To evaluate expectoration parameters and bronchial cell behavior in vitro, laboratories utilize Air-Liquid Interface (ALI) primary human bronchial epithelial cell cultures. ALI models allow respiratory cells to differentiate into pseudostratified, ciliated, and mucin-secreting goblet cells, closely mimicking in vivo airway architecture.
In these systems, research-grade Bronchogen is introduced to the basolateral media chamber. Researchers measure endpoints including:
• MUC5AC Mucin Secretion: Quantified via enzyme-linked immunosorbent assay (ELISA) of apical washings. • Trans-Epithelial Electrical Resistance (TEER): Measured via volt-ohmmeters to evaluate tight junction permeability and barrier integrity. • Gene Expression Profiling: Conducted using real-time quantitative PCR (RT-qPCR) targeting inflammatory pathways (NF-kB, IL-6, TNF-alpha) and cellular differentiation factors. • Ciliary Beat Dynamics: Assayed via high-speed digital microscopy to evaluate clearance velocity.
Utilizing verified, high-purity peptides ensures that changes in TEER values or cytokine release are attributable strictly to Bronchogen activity rather than trace endotoxins or synthesis contaminants.
Bacterial endotoxins (lipopolysaccharides, LPS) represent a major confounding variable in pulmonary cell line research. Because respiratory epithelial cells and pulmonary macrophages express high levels of Toll-Like Receptor 4 (TLR4), minute amounts of endotoxin in peptide preparations can trigger significant inflammatory artifact signals.
When unverified peptides containing trace LPS are introduced to bronchial cultures, researchers may falsely attribute cytokine upregulation, goblet cell hypersecretion, or cellular apoptosis to the peptide itself. PX1 Research mitigates this risk by subjecting all peptide lots to stringent LAL chromogenic endotoxin assays, ensuring levels remain strictly below <0.01 EU/mg.
This level of endotoxin control guarantees that experimental outcomes accurately reflect the innate bioregulatory actions of Bronchogen rather than artifactual TLR4 activation.
High-throughput screening assays, multi-center animal studies, and longitudinal cell culture projects require substantial quantities of uniform, lot-matched research peptides. Variability between production runs can introduce batch-dependent noise that compromises statistical power and reproducibility.
PX1 Research offers comprehensive institutional purchasing programs through our wholesale portal. We provide custom batch sizes, unified lot matching across bulk orders, and extended analytical validation documentation to support grant applications and regulatory compliance.
All orders ship directly from our USA distribution hubs in California and Arizona, utilizing automated order processing with same-day dispatch for orders finalized before standard cutoff times, ensuring seamless supply chain continuity for critical experimental timelines.
What is the primary application of Bronchogen in research?
Bronchogen is supplied strictly as a research-grade compound for in-vitro cell culture assays and preclinical animal models. It is studied primarily for its effects on bronchial epithelial gene expression, goblet cell hypersecretion, inflammatory cytokine suppression, and expectoration dynamics.
How does PX1 Research verify Bronchogen peptide purity?
PX1 Research verifies each lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity exceeding 98% and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular identity. Analytical testing is performed by independent ISO 17025 accredited laboratories.
What endotoxin limits are enforced on PX1 Research Bronchogen?
Every lot of Bronchogen undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain below 0.01 EU/mg, preventing false TLR4 receptor activation in sensitive respiratory cell lines.
How should lyophilized Bronchogen be stored upon receipt?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment away from light. Under proper freezing conditions, the lyophilized peptide maintains stability for up to 24 months.
What solvents are recommended for reconstituting Bronchogen in lab settings?
For cell culture assays, reconstitute Bronchogen in sterile Phosphate-Buffered Saline (PBS, pH 7.4). For multi-dose laboratory applications, sterile Bacteriostatic Water (0.9% benzyl alcohol) is recommended to prevent microbial growth.
What is the molecular formula and amino acid sequence of Bronchogen?
Bronchogen is a synthetic peptide bioregulator consisting of the short amino acid sequence Ala-Glu-Asp-Leu (Alanine-Glutamic Acid-Aspartic Acid-Leucine).
How does Bronchogen compare to Chonluten in respiratory studies?
Both Bronchogen and Chonluten belong to the short bioregulator peptide family. While Bronchogen focuses heavily on bronchial mucosal dynamics and goblet cell secretion parameters, Chonluten is frequently evaluated in models focusing on broader lung tissue repair and structural epithelial restoration.
Where are PX1 Research peptides manufactured and shipped from?
PX1 Research products are manufactured in compliant USA facilities and dispatched directly from our primary distribution hubs in California and Arizona with same-day shipping on standard business days.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.